$5.61
+0.58
(+11.53%)▲
Insights on Airsculpt Technologies
Revenue is down for the last 2 quarters, 55.70M → 46.79M (in $), with an average decrease of 16.0% per quarter
Netprofit is down for the last 2 quarters, 1.77M → -1.66M (in $), with an average decrease of 193.9% per quarter
11.22%
Downside
Day's Volatility :11.38%
Upside
0.18%
47.24%
Downside
52 Weeks Volatility :70.22%
Upside
43.56%
Period | Airsculpt Technologies | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -28.08% | -1.3% | 0.0% |
6 Months | -31.59% | 1.2% | 0.0% |
1 Year | 52.86% | -5.7% | -6.5% |
3 Years | -64.69% | 18.2% | -3.8% |
Market Capitalization | 311.4M |
Book Value | $1.48 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.13 |
Wall Street Target Price | 8.15 |
Profit Margin | -3.76% |
Operating Margin TTM | 2.05% |
Return On Assets TTM | 0.87% |
Return On Equity TTM | -9.06% |
Revenue TTM | 189.0M |
Revenue Per Share TTM | 3.35 |
Quarterly Revenue Growth YOY | 20.3% |
Gross Profit TTM | 110.5M |
EBITDA | 12.5M |
Diluted Eps TTM | -0.13 |
Quarterly Earnings Growth YOY | 2.0 |
EPS Estimate Current Year | 0.02 |
EPS Estimate Next Year | 0.21 |
EPS Estimate Current Quarter | -0.02 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 45.28%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 41.2M | - |
Net Income | -5.1M | - |
Net Profit Margin | -12.34% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 62.8M | ↑ 52.21% |
Net Income | 5.8M | ↓ 213.03% |
Net Profit Margin | 9.16% | ↑ 21.5% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 133.3M | ↑ 112.4% |
Net Income | 10.6M | ↑ 83.5% |
Net Profit Margin | 7.91% | ↓ 1.25% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 168.8M | ↑ 26.61% |
Net Income | -14.7M | ↓ 239.12% |
Net Profit Margin | -8.7% | ↓ 16.61% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 49.7M | ↑ 25.57% |
Net Income | 583.0K | ↓ 184.13% |
Net Profit Margin | 1.17% | ↑ 2.92% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 38.9M | ↓ 21.67% |
Net Income | -7.4M | ↓ 1365.35% |
Net Profit Margin | -18.97% | ↓ 20.14% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 40.7M | ↑ 4.66% |
Net Income | -7.2M | ↓ 2.51% |
Net Profit Margin | -17.67% | ↑ 1.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 45.8M | ↑ 12.55% |
Net Income | -14.0K | ↓ 99.81% |
Net Profit Margin | -0.03% | ↑ 17.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 55.7M | ↑ 21.59% |
Net Income | 1.8M | ↓ 12785.71% |
Net Profit Margin | 3.19% | ↑ 3.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 46.8M | ↓ 16.0% |
Net Income | -1.7M | ↓ 193.86% |
Net Profit Margin | -3.56% | ↓ 6.75% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 171.5M | - |
Total Liabilities | 51.1M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 179.6M | ↑ 4.73% |
Total Liabilities | 55.9M | ↑ 9.44% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 200.6M | ↑ 11.66% |
Total Liabilities | 117.0M | ↑ 109.22% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 200.8M | ↑ 0.1% |
Total Liabilities | 130.0M | ↑ 11.08% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 218.8M | ↑ 5.57% |
Total Liabilities | 121.3M | ↑ 3.39% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 193.9M | ↓ 11.36% |
Total Liabilities | 121.4M | ↑ 0.09% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 200.8M | ↑ 3.53% |
Total Liabilities | 130.0M | ↑ 7.04% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 209.5M | ↑ 4.36% |
Total Liabilities | 134.3M | ↑ 3.31% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 217.3M | ↑ 3.71% |
Total Liabilities | 135.8M | ↑ 1.13% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 204.1M | ↓ 6.06% |
Total Liabilities | 119.9M | ↓ 11.69% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.9M | - |
Investing Cash Flow | -4.4M | - |
Financing Cash Flow | -783.0K | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.0M | ↑ 182.64% |
Investing Cash Flow | -3.7M | ↓ 16.9% |
Financing Cash Flow | -5.0M | ↑ 540.74% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 26.6M | ↑ 90.82% |
Investing Cash Flow | -7.1M | ↑ 92.9% |
Financing Cash Flow | -4.5M | ↓ 9.33% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 24.4M | ↓ 8.21% |
Investing Cash Flow | -12.9M | ↑ 81.58% |
Financing Cash Flow | -27.3M | ↑ 499.19% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 10.4M | ↑ 46.86% |
Investing Cash Flow | -1.9M | ↓ 56.36% |
Financing Cash Flow | -509.0K | ↓ 44.91% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 329.0K | ↓ 96.84% |
Investing Cash Flow | -4.6M | ↑ 145.95% |
Financing Cash Flow | -23.4M | ↑ 4496.27% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.6M | ↑ 1918.24% |
Investing Cash Flow | -2.2M | ↓ 52.15% |
Financing Cash Flow | -2.4M | ↓ 89.62% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.2M | ↓ 6.34% |
Investing Cash Flow | -3.8M | ↑ 73.8% |
Financing Cash Flow | -737.0K | ↓ 69.66% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 12.2M | ↑ 96.75% |
Investing Cash Flow | -2.2M | ↓ 43.36% |
Financing Cash Flow | -579.0K | ↓ 21.44% |
Sell
Neutral
Buy
Airsculpt Technologies is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Airsculpt Technologies | -6.19% | -31.59% | 52.86% | -64.69% | -64.69% |
![]() Fresenius Medical Care Ag & Co. Kgaa | 20.12% | -5.08% | 26.5% | -50.8% | -50.54% |
![]() Hca Holdings, Inc. | 10.72% | -7.99% | 5.58% | 65.37% | 72.51% |
![]() Universal Health Services Inc. | 9.19% | 1.65% | 6.46% | 4.31% | 0.53% |
![]() Davita Healthcare Partners Inc. | 34.06% | 5.64% | 40.31% | -3.74% | 57.14% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Airsculpt Technologies | 100.0 | NA | NA | 0.02 | -0.09 | 0.01 | 0.0 | 1.48 |
![]() Fresenius Medical Care Ag & Co. Kgaa | 23.89 | 23.89 | 1.06 | 1.95 | 0.04 | 0.02 | 0.03 | 47.74 |
![]() Hca Holdings, Inc. | 12.45 | 12.45 | 1.37 | 18.2 | 0.21 | 0.11 | 0.01 | -9.21 |
![]() Universal Health Services Inc. | 14.41 | 14.41 | 1.87 | 10.3 | 0.11 | 0.05 | 0.01 | 88.85 |
![]() Davita Healthcare Partners Inc. | 15.41 | 15.41 | 0.86 | 7.83 | 0.34 | 0.05 | 0.11 | 13.13 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Airsculpt Technologies | Buy | $311.4M | -64.69% | 100.0 | -3.76% |
![]() Fresenius Medical Care Ag & Co. Kgaa | Hold | $11.8B | -50.54% | 23.89 | 2.31% |
![]() Hca Holdings, Inc. | Buy | $67.5B | 72.51% | 12.45 | 9.05% |
![]() Universal Health Services Inc. | Hold | $9.4B | 0.53% | 14.41 | 4.82% |
![]() Davita Healthcare Partners Inc. | Hold | $9.1B | 57.14% | 15.41 | 5.11% |
Vesey Street Capital Partners, L.L.C.
SW Investment Management LLC
Balyasny Asset Management LLC
BlackRock Inc
Bandera Partners LLC
Vanguard Group Inc
at elite body sculpture we focus on body contouring. using our minimally invasive and patented airsculpt® technology, our procedures are geared to make healing faster with less bruising and less trauma to the area being treated. our commitment is to provide the very best possible results for each patient, using the most up to date and advanced technology.
Organization | Airsculpt Technologies |
Employees | 291 |
CEO | Dr. Aaron J. Rollins M.D. |
Industry | Healthcare |
Lemaitre Vascular Inc
$5.61
+11.53%
Exscientia Plc
$5.61
+11.53%
22nd Century Group Inc
$5.61
+11.53%
Eagle Pharmaceuticals Inc.
$5.61
+11.53%
Dynavax Technologies Corporation
$5.61
+11.53%
Avanos Medical, Inc.
$5.61
+11.53%
Scilex Holding Co
$5.61
+11.53%
Novavax, Inc.
$5.61
+11.53%
Agios Pharmaceuticals, Inc.
$5.61
+11.53%